UK patients enabled access to transformative new medicines in shortest time possible via new, integrated Innovative Licensing and Access Pathway 

Twitter

Linkedin

Facebook

email

It is the only example globally of an end-to-end access pathway, where a medicine developer can work collaboratively with the national health system, the regulator, and health technology assessment bodies from the early stag…

Follow this news feed: